Novavax initiates PREVENT-19 study of booster doses of COVID-19 vaccine_老虎社区_美港股上老虎

Novavax initiates PREVENT-19 study of booster doses of COVID-19 vaccine

seekingalpha2021-12-22

Novavax(NASDAQ:NVAX)announces that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, have been administered in an extension of the company's PREVENT-19 Phase 3 trial. The study will ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

ojxp
·2021-12-22
Like and comment please
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1199292313?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-22 16:55","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1199292313","market":"us","top_or_hot":-1,"title":"Novavax initiates PREVENT-19 study of booster doses of COVID-19 vaccine","media":"seekingalpha","content":"<div>\n<p>Novavax(NASDAQ:NVAX)announces that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, have been administered in an extension of the company's PREVENT-19 Phase 3 trial.\nThe study will ...</p>\n\n<a href=\"https://seekingalpha.com/news/3782554-novavax-initiates-prevent-19-study-of-booster-doses-of-covid-19-vaccine\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax initiates PREVENT-19 study of booster doses of COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax initiates PREVENT-19 study of booster doses of COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 16:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3782554-novavax-initiates-prevent-19-study-of-booster-doses-of-covid-19-vaccine><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)announces that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, have been administered in an extension of the company's PREVENT-19 Phase 3 trial.\nThe study will ...</p>\n\n<a href=\"https://seekingalpha.com/news/3782554-novavax-initiates-prevent-19-study-of-booster-doses-of-covid-19-vaccine\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://seekingalpha.com/news/3782554-novavax-initiates-prevent-19-study-of-booster-doses-of-covid-19-vaccine","article_id":"1199292313","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199292313","pubTimestamp":1640163312,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Novavax(NASDAQ:NVAX)announces that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, hav","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯医药启动新冠肺炎疫苗强化剂量的预防-19研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax(NASDAQ:NVAX)announces that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, have been administered in an extension of the company's PREVENT-19 Phase 3 trial.\nThe study will evaluate the safety and efficacy of a heterologous or homologous third dose of NVX-CoV2373.\nThe booster dose is identical to the active vaccine previously administered to the participants in a two-dose regimen (5 micrograms of recombinant Spike protein plus 50 micrograms of Matrix-M adjuvant) and may be administered at least six months after receipt of active vaccine.\nThe primary endpoint is the first occurrence of polymerase chain reaction (PCR)-confirmed mild, moderate or severe COVID-19 with onset at least seven days after the third (booster) vaccine dose.\nEarlier,WHO issued recommendations for administering Novavax's COVID vaccine.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":691810474,"gmtCreate":1640163723662,"gmtModify":1640163724089,"author":{"id":"3581477238019949","authorId":"3581477238019949","name":"ojxp","avatar":"https://static.tigerbbs.com/f1cc2cda3ae5a57a5a3b43f6c0c4e93e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581477238019949","authorIdStr":"3581477238019949"},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691810474","repostId":1199292313,"repostType":4,"repost":{"id":"1199292313","pubTimestamp":1640163312,"share":"https://www.laohu8.com/m/news/1199292313?lang=&edition=full","pubTime":"2021-12-22 16:55","market":"us","language":"en","title":"Novavax initiates PREVENT-19 study of booster doses of COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1199292313","media":"seekingalpha","summary":"Novavax(NASDAQ:NVAX)announces that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, hav","content":"<p>Novavax(NASDAQ:NVAX)announces&nbsp;that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, have been administered in an extension of the company's PREVENT-19 Phase 3 trial.</p>\n<p>The study will evaluate the safety and efficacy of a heterologous or homologous third dose of NVX-CoV2373.</p>\n<p>The booster dose is identical to the active vaccine previously administered to the participants in a two-dose regimen (5 micrograms of recombinant Spike protein plus 50 micrograms of Matrix-M adjuvant) and may be administered at least six months after receipt of active vaccine.</p>\n<p>The primary endpoint is the first occurrence of polymerase chain reaction (PCR)-confirmed&nbsp;mild, moderate or severe COVID-19 with onset at least seven days after the third (booster) vaccine dose.</p>\n<p>Earlier,WHO issued recommendations for administering Novavax's COVID vaccine.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax initiates PREVENT-19 study of booster doses of COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax initiates PREVENT-19 study of booster doses of COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 16:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3782554-novavax-initiates-prevent-19-study-of-booster-doses-of-covid-19-vaccine><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)announces that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, have been administered in an extension of the company's PREVENT-19 Phase 3 trial.\nThe study will ...</p>\n\n<a href=\"https://seekingalpha.com/news/3782554-novavax-initiates-prevent-19-study-of-booster-doses-of-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3782554-novavax-initiates-prevent-19-study-of-booster-doses-of-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1199292313","content_text":"Novavax(NASDAQ:NVAX)announces that the first booster doses of its COVID-19 vaccine, NVX-CoV2373, have been administered in an extension of the company's PREVENT-19 Phase 3 trial.\nThe study will evaluate the safety and efficacy of a heterologous or homologous third dose of NVX-CoV2373.\nThe booster dose is identical to the active vaccine previously administered to the participants in a two-dose regimen (5 micrograms of recombinant Spike protein plus 50 micrograms of Matrix-M adjuvant) and may be administered at least six months after receipt of active vaccine.\nThe primary endpoint is the first occurrence of polymerase chain reaction (PCR)-confirmed mild, moderate or severe COVID-19 with onset at least seven days after the third (booster) vaccine dose.\nEarlier,WHO issued recommendations for administering Novavax's COVID vaccine.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":29,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}